Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.

Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous.

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.

Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe

Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard intravenous (IV) infusion of Tecentriq (atezolizumab).2 It will be available for all IV indications of Tecentriq approved for adults in the U.S., including certain types of lung, liver, skin and soft tissue cancer.3

FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple sclerosis.

US FDA approves injectable version of Roche's multiple sclerosis therapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes, compared with 30-60 minutes for standard IV i.

FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Eli Lilly

Novartis

Pfizer

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.

Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

Novo Nordisk

The company's stock was falling after a report detailing side effects from its once-daily weight-loss pill.

Roche Setback Is Big for Eli Lilly, Novo Nordisk as Obesity Drug Battle Ramps Up

Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans.

Roche shares drop on side effects result in early-stage obesity pill trial

The storied European pharmaceutical is forging ahead in its efforts to develop a weight loss treatment. Recent news from the lab about the medication is not encouraging, however.

Why Roche Holdings Stock Withered on Wednesday

Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.

Roche says early-stage obesity pill results were based on just six patients

Roche stock has risen 22% since May due to promising GLP-1 agonist drug candidates, despite recent setbacks with CT-388's side effects. Roche's GLP-1 pipeline includes CT-388, CT-996 and CT-868, aiming to compete with Lilly and Novo's blockbuster weight loss drugs. Roche's core business remains strong, with Q2 2024 revenues up and guidance raised, providing a hedge against potential GLP-1 program failures.

Roche: Why I'm Not Concerned About Slight Sell-Off On Weight Loss Drug Safety Data

Basel, 10 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the opening of its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland. Equipped with cutting-edge technologies and housing around 1,000 state-of-the-art laboratory and office workplaces, the new center brings together teams of scientists and researchers to accelerate scientific discoveries for patients.

Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation

Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea , Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced its collaboration with Roche to integrate Lunit SCOPE PD-L1 22C3 TPS into Roche's navify ® Digital Pathology platform.

Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing

Amazon

General Electric

Amazon, Roche, GE Aerospace, Canterbury Park and NVE are included in this Analyst Blog.

The Zacks Analyst Blog Amazon, Roche, GE Aerospace, Canterbury Park and NVE

Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world's largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche's navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform. Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world's largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche's navify® Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses directly from navify® Digital Pathology platform.

Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics

The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare. Roche is now integrating more than 20 artificial intelligence (AI) algorithms from eight new collaborators into its digital pathology open environment.

Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment

Basel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week data for the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open-label extension (OLE) study at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark on 18 September 2024. Results demonstrate that patients with relapsing multiple sclerosis (RMS) treated with fenebrutinib for up to one year maintained very low levels of disease activity and no disability progression.

Roche's fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis

Amgen

Viking Therapeutics

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.

Roche Obtains Approval For its Rare Blood Disorder Drug in the EU

Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents (12 years of age or older with a weight of 40 kg and above) with paroxysmal nocturnal haemoglobinuria (PNH) who are either new to, or have been previously treated with C5 inhibitors. PNH is a rare and life-threatening blood condition where red blood cells are destroyed by the complement system – part of the innate immune system – causing symptoms such as anaemia, fatigue and blood clots, and potentially leading to kidney disease.4

Roche's PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Roche Holding (RHHBY) Rating Upgrade to Strong Buy

Southside Bancshares

APELY, RHHBY, and SBSI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 23, 2024.

News for Roche Holding AG Stock (RHHBY)